Supernus Pharmaceuticals Inc
F:S49
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Supernus Pharmaceuticals Inc
F:S49
|
US |
|
R
|
Ramada Investimentos e Industria SA
F:Y4E
|
PT |
|
S
|
Sturm Ruger & Company Inc
F:ST2
|
US |
|
Pattern SpA
MIL:PTR
|
IT |
|
SB Financial Group Inc
F:9KH
|
US |
|
Fresenius Medical Care AG
XMUN:FME
|
DE |
|
Compagnie Generale des Etablissements Michelin SCA
PAR:ML
|
FR |
|
K
|
Kellogg Co
F:KEL
|
US |
|
P
|
Pinnacle West Capital Corp
LSE:0KIT
|
US |
|
R
|
Revo Insurance SpA
F:H0O
|
IT |
|
D
|
DigitalOcean Holdings Inc
XMUN:0SU
|
US |
|
C
|
Camden Property Trust
F:CAL
|
US |
Wall St Price Targets
S49 Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for S49 is 56.82 EUR with a low forecast of 49.25 EUR and a high forecast of 61.44 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S49's stock price target?
Price Target
56.82
EUR
According to Wall Street analysts, the average 1-year price target for S49 is 56.82 EUR with a low forecast of 49.25 EUR and a high forecast of 61.44 EUR.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
62%
The compound annual growth rate for Operating Income over the next 8 years is 62%.
